A duo of genetic mutations that typically signals a 'death sentence' in most cancers actually helps patients with stomach cancer live longer.
March 31, 2026
Original Paper
Cancer-Type Specific Prognostic Impact of Concurrent TP53 and KRAS Alterations: A Multi-Cohort Genomic Analysis
medRxiv · 10.64898/2026.03.29.26349383
The Takeaway
KRAS and TP53 are two of the most dangerous drivers of cancer, and having both mutated at once usually indicates a very aggressive, fatal disease. However, researchers discovered that in gastric cancer, patients with this specific combination surprisingly have the longest survival rates, revealing that 'bad' mutations can have completely opposite effects depending on the organ.
From the abstract
Background: The tumor suppressor gene TP53 and the oncogene KRAS are among the most frequently altered core drivers in human malignancies. Although they cooperatively regulate critical biological processes, the prognostic impact of their co alterations remains poorly defined and exhibits striking inconsistency across different cancer types. Methods: We comprehensively analyzed genomic and clinical data from multi-cancer cohorts sourced from the cBioPortal database and The Cancer Genome Atlas (TC